OraSure Reports Q1 ’24 Revenue of $54.1 Million
May 08, 2024 16:05 ET
|
OraSure Technologies, Inc.
Q1 GAAP EPS of $(0.05); Q1 Non-GAAP EPS of $0.04 Restructuring initiatives expected to result in $15 million of annualized expense reductions once fully implemented and position OraSure to achieve...
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 08, 2024 16:05 ET
|
Assembly Biosciences, Inc.
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on...
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
May 08, 2024 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024 16:02 ET
|
Olema Oncology
Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination study to...
Sunrun Reports First Quarter 2024 Financial Results
May 08, 2024 16:01 ET
|
Sunrun Inc.
Sunrun Reports First Quarter 2024 Financial Results
Duolingo Reports 45% Revenue Growth and Record Profitability in First Quarter 2024; Raises Full Year Guidance
May 08, 2024 16:01 ET
|
Duolingo, Inc.
PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- Duolingo, Inc. (NASDAQ: DUOL), the world’s leading mobile learning platform, announced results for the first quarter ended March 31, 2024 in a...
Cytokinetics Reports First Quarter 2024 Financial Results
May 08, 2024 16:00 ET
|
Cytokinetics, Incorporated
Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress Opened...
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
May 08, 2024 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Intermex Reports First Quarter Results
May 08, 2024 08:00 ET
|
International Money Express, Inc.
Company generates strong earnings and margins, continued execution of omnichannel strategy Company to Host Conference Call Today at 9 a.m. ET MIAMI, May 08, 2024 (GLOBE NEWSWIRE) -- International...
Brink's Announces Strong First-Quarter Results and Affirms Full Year Guidance
May 08, 2024 07:00 ET
|
The Brink’s Company
Record First Quarter Revenue Reflecting 4% Growth and 12% Organic GrowthGAAP net income up 229% to $49M and record adjusted EBITDA up 15% to $218MGAAP EPS up 263% to $1.09 and non-GAAP EPS up 20% to...